Heparan sulfate proteoglycans (HSPGs) play a critical role in the interaction of tumor cells and their microenvironment. HSPG activity is dictated by sulfation patterns controlled by sulfotransferases, which add sulfate groups, and sulfatases (Sulfs), which remove 6-O-sulfates. Here we report altered expression of these enzymes in human neuroblastoma cells with higher levels of Sulf-2 expression a specific feature of MYCN- 
Introduction
Heparan sulfate proteoglycans (HSPGs) present at the surface and in the extracellular milieu of normal and malignant cells bind to a large variety of proteins, contributing to the mechanisms that control the communication between cells and their microenvironment (1, 2) . In the extracellular milieu, proteoglycans serve as a reservoir of growth factors, cytokines and chemokines, regulating their bioavailability and binding to their receptors (3, 4) . Proteoglycans play an important role in normal biological processes including organ development and tissue repair, as well as in pathological conditions such as inflammation and cancer (3, 5) . Their role in cancer is, however, complex and includes anti-as well as pro-tumorigenic effects. This is in part due to the significant enzymatic modifications that these molecules undergo both intra-and extracellularly. Recently attention has been focused on two extracellular sulfatases (Sulf-1 and Sulf-2) that selectively remove 6-O-sulfate groups from glucosamine residues, and thereby remodel HS chain sulfation (6) . Sulfs have been implicated as inhibitors of tumor growth in some cancers (7) , where they have a bimodal effect (8) (9) (10) , but are more commonly reported as being pro-tumorigenic (11) (12) (13) (14) . The mechanism by which Sulfs contribute to tumorigenesis involves the modulation of ligand-receptor interactions and activation of downstream signaling pathways. By remodeling 6-O sulfation in HSPGs, Sulf-1 promotes Wnt signaling by increasing the interaction between Wnt and its receptor Frizzled (15) , while Sulf-2 enhances the interaction between platelet-derived growth factor (PDGF) and its receptor PDGFRα (14) .
Neuroblastoma is the most common extracranial solid tumor in children and a cancer that has a high potential to metastasize (16) . In 40% of high-risk neuroblastoma cases, amplification of the MYCN (MYCN-A) oncogene has been identified as the oncogenic event responsible for aggressive progression and poor clinical outcome (17) . The mechanisms by which MYCN promotes tumorigenesis are complex and linked primarily to its transcriptional activity, upregulating the expression of a large variety of genes involved in proliferation, survival, differentiation, DNA repair, drug resistance and angiogenesis (18, 19 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 27, 2014; DOI: 10.1158/0008-5472.CAN- role that HSPGs play in the regulation of the interactions between tumor cells and the TME, their potential contribution in neuroblastoma progression was examined. Neuroblastoma cells have been shown to produce both cell surface and extracellular HSPGs (20, 21) 
Cell transfection
Transfection of siRNA was in the presence of Lipofectamine RNAiMax (Life Technologies) according to the manufacturer's instructions. SiRNA oligonucleotides (sequences provided in Table 1 in Supplementary Data) were obtained from Life Technologies (Silencer Select Sulf-2, s31805, s31806; negative control AM4611). Two Sulf-2 overexpressing constructs, a full length Sulf-2 and a catalytically inactive Sulf-2 (S2ΔCC) form with a mutation (C88A) were used (Addgene, plasmid 13004 and 13006).
For shRNA, two previously published target regions of Sulf-2 [GGAGTGGTGGTGTCAATAA (1143) and GCTGAAGCTGCATAAGTGC (1413)] were used with AACAGTCGCGTTTGCGACTGG as a control (scrambled) (23) . The pLVTHM backbone (Addgene plasmid#12247) was used to insert the Sulf-2 oligonucleotides. Inserted sequences where subcloned into tet-inducible shRNA lentiviral vectors pLVCT-tTR-KRAB (Addgene plasmid #11643).Plasmid deposition was verified by sequencing (GENEWIZ) using the human H1 promoter forward primer and/or SP6 forward primers.
Cell viability, proliferation and apoptosis assays
CellTiter-Glo Luminescent cell viability assay (Promega #G7570) was used. For crystal violet staining, cells were fixed with 4% paraformaldehyde and subsequently stained with 1% crystal violet for 30 minutes. For apoptosis assays, cells were analyzed for caspase 3/7 activity (ApoLive-Glo Multiplex Assay; Promega #G6410). Alternatively, cells were grown in 6-well plates (4x10 5 cells/well) and Annexin V expression and propidium iodide staining (PI) were performed (FITC Annexin V Apoptosis Detection kit, BD Pharmingen #556547). Cell cycle analysis was performed as previously described (24) using a FITC BrdU Flow kit (BD Pharmingen #552598). Annexin V and BrdU were analyzed by flow cytometry using CellQuestPro software.
Gene expression analysis
Total RNA was extracted from cell lysates using RNeasy kit (Qiagen) and reverse transcribed into complementary DNA (cDNA) using SuperScript III Reverse Transcriptase (Invitrogen). RT-PCR was performed with cDNA corresponding to 50 ng total RNA using the LightCycler ® Roche 480 system (Roche) and the primers listed in Table 1 of Supplementary Data.
Western blot analysis
Western blots were performed using the following monoclonal antibodies (MAb) antibodies: Signaling #9665, 1:1000 dilution), an anti-cleaved caspase 3 rabbit MAb (Cell Signaling #9661, 1:1000,dilution), an anti-β-actin rabbit MAb (Sigma Aldrich #A2066, 1:3000 dilution) and an anti-β-tubulin mouse MAb (Sigma Aldrich #T4026, 1:1000 dilution). Analyses of the membranes were performed with the Li-Cor Odyssey infrared imager using an anti-mouse IgG IRdye 680 (Li-Cor #926-32220) and an anti-rabbit IgG IRdye 800 (Li-Cor #926-32211) as secondary antibodies (1:5000).
Animal experiments
In vivo experiments were performed in accordance with a protocol approved by the 
Gene expression microarray data
The gene expression studies were performed on neuroblastoma datasets published previously (27, 28) . The GSE16716 data set was obtained from samples of patients enrolled in clinical trials conducted by the German Consortium, Society of Pediatric Oncology and Hematology (GPOH). The GSE3446 dataset included 162 patients enrolled in clinical trials conducted by the COG. The transcript level data of array probes for each sample were 9 obtained as log 2 expression levels and averaged using the gene symbol annotations provided by the manufacturer.
Statistical analysis
Differences between groups were compared using Student's t-test or Analysis of Variance (ANOVA) as appropriate, with log 10 transformation to normalize the data and stabilize variance when necessary. Comparisons of event-free survival between groups of patients were based on the univariate or stratified logrank test as appropriate. Survival curves were based on the product-limit estimate (29) . P-values are based on two-sided tests unless otherwise specified.
Statistical computations were performed using Stata 11 (Stata Statistical Software: Release 11.
College Station, TX: StataCorp LP) Statistical analysis for the gene expression microarray data was performed with R Project Software (version 3.0.1) with one-way ANOVA followed by Wald's test for comparing differences between multiple groups and correcting for multiple testing when appropriate. Differences were considered significant at p < 0.05. 
Results

Sulf-2 is specifically overexpressed in MYCN-A neuroblastoma cell lines
To explore the role of HS in neuroblastoma, we started with an unbiased analysis of the expression of key enzymes controlling their sulfation patterns, focussing on the biosynthetic STs, and Sulfs that remove 6-O-sulfate from glucosamine residues. The analysis ( Figure Figure S2 ). Thus, among the enzymes controlling the pattern of sulfation of HSPGs, Sulf-2 was the only one that was differentially expressed in MYCN-A cell lines compared to all other cell lines. The data also demonstrated that higher levels of Sulf-2 were associated with a decrease in the level of sulfation of HSPG. These data led us to explore whether Sulf-2 could play an active role in MYCN-A -driven neuroblastoma.
Sulf-2 increases neuroblastoma cell survival and its expression is linked to MYCN.
To address this question, we first examined the effect of overexpression of Sulf-2 on the survival of 2 MYCN-NA cell lines ( Figure 3A and B) . This analysis revealed that overexpression of Sulf-2 WT was associated with a corresponding increase in cell viability in cultures compared to untransfected parental cells, whereas overexpression of a catalytically inactive S2ΔCC mutant had no effect. Importantly, the data also show that overexpression of Sulf-2 did not affect Figure 4D ). An analysis of the cell cycle distribution indicated a decrease in S and in G2 phases (from 9.5% to 4.4%) and an increase in the sub-G0 cell population (from 4% to 22%) suggesting an effect on both cell cycle entry and apoptosis ( Figure 3E ).This was confirmed by demonstrating an increase in caspase 3/7 activity upon Sulf-2 KD in SK-N-BE (2) and NB-19 cells (Figure 5A ), an increase in cleaved PARP and cleaved caspase 3 in Sulf-2 siRNA1-and 2-expressing cells ( Figure 5B ) and a corresponding increase in Annexin-V expression in NB-19 cells ( Figure 5C ). The data indicated that suppression of Sulf-2 expression in MYCN-A neuroblastoma cells decreased proliferation and increased apoptosis, supporting the hypothesis that Sulf-2 expression is linked to MYCN, and is an active contributor to the protumorigenic function of MYCN.
Downregulation of Sulf-2 expression in MYCN-A cells decreases tumor formation and tumor growth in xenotransplanted mice
We then tested whether Sulf-2 would contribute to MYCN activity in vivo. SK-N-BE(2) cells were transfected with a doxycycline-regulated Sulf-2 shRNA lentiviral vector (pKRAB-Sulf-2) or control (pKRAB-SCR) and stably transfected GFP-positive cells were sorted by flow cytometry. 
Treatment of these cells with doxycycline in vitro decreased Sulf-2 expression (Figure 6 A) . We also noted that, in the absence of doxycycline, there was a partial decrease in Sulf-2 expression in pKRAB-Sulf-2 transfected cells compared to pKRAB-SCR cells suggesting "leaky" expression of the shRNA in the absence of doxycycline, as reported by others (32) . . Downregulation of Sulf-2 in these cells by doxycycline treatment resulted in decreased viability in vitro (Figure 6 B) .
These cells were then injected subcutaneously at 2 sites in NOD/SCID mice and monitored for growth ( Figure 6 C and D) . In each group (n=9 or 10 mice), 5 mice received doxycycline in the drinking water. In the 9 mice injected with SK-N-BE(2) pKRAB-SCR vector, 8 mice developed bilateral tumors and the administration of doxycycline had no effect on the rate of tumor growth (one mouse in the doxycycline negative group did not develop tumors). By day 31 after tumor cell implantation, all mice had to be euthanized because one or both tumors had reached a volume greater than 1,500 mm 3 ( Figure 6C ).
In the group of mice injected with SK-N-BE (2) that higher levels of Sulf-2 expression were significantly associated with a lower EFS and predictor of poor clinical outcome (logrank p < 0.001). However, owing to its strong association with MYCN expression, Sulf-2 expression was not found to be an independent prognosticator after controlling for risk amplification status and risk group (stratified logrank p = 0.96 and p=0.12 for GPOH and COG patients, respectively). Altogether these correlative data provide further support to the hypothesis that Sulf-2 contributes to the tumorigenic function of MYCN. 
that specific inhibitors of Sulf-2 could be developed (50) . Considering the importance of targeting MYCN, this avenue should be actively explored.
In conclusion, our data point to Sulf-2 as regulator of HS sulfation being downstream of MYCN and an important contributor to its oncogenic function. They also emphasize the critical role that HSPGs could play as regulators of survival and proliferation in neuroblastoma, a subject that has not been investigated so far. 
